400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / GPCR/G Protein / cAMP / 毛喉素
CAS No.: 66575-29-9
Synonyms: 毛喉素;Coleonol;Colforsin
Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types with binding (IC50=41 nM) to and activation (EC50=0.5 μM) of type I adenylyl cyclase. It is commonly used to raise levels of cAMP in the research of cell physiology.
生物活性
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT03390985 | - | - | Completed | - | - |
NCT02586883 | Idiopathic Dilation of the Bro... more >>nchi Collapse << | Not Applicable | Recruiting | April 2020 | France ... more >> Necker-Enfants Malades Hospital Recruiting Paris, France, 75015 Contact: Isabelle SERMET-GAUDELUS, MD, PhD +33144494887 isabelle.sermet@nck.aphp.fr Collapse << |
NCT03455153 | - | - | Completed | - | United Kingdom ... more >> Lindum Medical Practice Lincoln, Lincolnshire, United Kingdom, LN2 2JP Nettleham Medical Practice Lincoln, Lincolnshire, United Kingdom, LN2 2RS Birchwood Medical Practice Lincoln, Lincolnshire, United Kingdom, LN6 0QQ Collapse << |
实验方案
技术信息
CAS号 | 66575-29-9 | 储存条件 |
|
|||||||||||||
分子式 | C22H34O7 | 运输 | 蓝冰 | |||||||||||||
分子量 | 410.50 | 别名 | 毛喉素;Coleonol;Colforsin;HL 362;佛司可林 | |||||||||||||
溶解度 |
|
动物实验配方 |
|
Cell Lines | Concentration | Assay Type | Time | Activity Description | Data Sources |
---|
3T3-L1 | 2.5/5 μM | Function Assay | 24 h | significantly decreases ATGL protein expression at all doses tested | 25590597 |
3T3-L1 preadipocytes | 10 μM | Function Assay | 12 h | induces CREB phosphorylation and C/EBPβ expression | 25928058 |
AML-12 | 20 μM | Function Assay | 3 h | upregulates the phosphorylation levels at Thr-411 and Ser-493 | 26048985 |
AML-12 | 20 μM | Function Assay | 1-8 h | increases glucose production | 26048985 |
AML-12 | 20 μM | Function Assay | 3 h | up-regulates Pgc1a, Pepck, and G6pc mRNA levels | 26048985 |
AML-12 | 20 μM | Function Assay | 3 h | induces the dephosphorylation of CRTC2 | 26048985 |
BAECs | 25 μM | Function Assay | 24 h | enhances the activation of PPARα by 5 μM resveratrol, T4HS, or 4-PAP | 25798826 |
BeWo | 25 μM | Function Assay | 24/48/72 h | leads to an increase in the expression of other fusion markers | 26053549 |
BeWo | 10 μM | Function Assay | 72 h | mediates BeWo cell differentiation | 25713425 |
BeWo | 20 µM | Function Assay | 48 h | increases the differentiation of BeWo cells | 25566740 |
BeWo | 20 µM | Function Assay | 48 h | increases the adhesion of THP-1 monocytes | 25566740 |
BeWo | 20 µM | Function Assay | 48 h | increases the beta-hCG release | 25362260 |
BeWo | 20 µM | Function Assay | 48 h | downregulates the level of TMEMF16 | 25362260 |
BeWo | 20 µM | Function Assay | 48 h | downregulates the level of GCM-1 | 25362260 |
BeWo | 20 µM | Function Assay | 48 h | induces cell fusion | 25184477 |
bovine oocytes | 100 μM | Function Assay | 12 h | inhibits the effect of NPPA and/or NPPC to stimulate resumption of meiosis | 26051611 |
C6 | 10 μM | Function Assay | 20 min | increases cAMP accumulation | 25069417 |
Caco-2 | 0.1/1/10 μM | Function Assay | 20 min | induces a dose-dependent increase in intracellular cAMP levels | 26049102 |
Caco-2 | 0.1/1/10 μM | Function Assay | 24 h | increases MRP2 protein level | 26049102 |
EM1 | 15 μM | Function Assay | 48 h | reduces the expression of LIF or PTGS2 in CALR- or EPAC2-silenced EM1 cells | 25378661 |
EndoC-βH1 | 5 μM | Function Assay | 1 h | potentiates glucose-induced insulin secretion in the presence of glucose | 26028562 |
EndoC-βH1 | 5 μM | Function Assay | 1 h | leads to a strong cAMP increase | 26028562 |
GH3 | 1 μM | Function Assay | 6-h | attenuates the correlation between PRL and Bmal1 expression | 25727018 |
GH3 | 1 μM | Function Assay | 6-h | induces PRL and Bmal1, but not Clock, mRNA expression | 25727018 |
GLUTag | 10 µM | Function Assay | 0/2/4 h | stimulates GLP-1 secretion cotreated with IBMX | 25832631 |
GLUTag | 10 µM | Function Assay | 4 h | increases the pCREB levels with the IBMX | 25832631 |
granulosa cells | 10 μM | Function Assay | 12/24 h | increases the levels of RGS2 mRNA | 25339105 |
granulosa cells | 10 μM | Function Assay | 12/24 h | increases the levels of reporter activity for the longest fragment (−854/+18RGS2.LUC) | 25339105 |
granulosa cells | 10 μM | Function Assay | 24 h | increases the intensity of DNA/protein complex | 25339105 |
granulosa cells | 10 μM | Function Assay | 24 h | increases the levels of RGS2 promoter activity | 25339105 |
H295R | 10 μM | Function Assay | 48 h | increases steroid metabolites in the androgen, mineralo- and glucocorticoid pathways | 25869556 |
H929 | 0-100 μM | Cell Viability Assay | 72 h | induces cell death dose dependently | 26306624 |
hADSCs | 5 µM | Function Assay | 30 min | increases cAMP levels | 25591908 |
HEK293 | 10 μM | Function Assay | 6 h | increases phosphorylation of overexpressed KLHL3 at S433 | 26435498 |
HEK293 | 5 µM | Function Assay | 30 min | increases cAMP levels | 25591908 |
HEK-293 | 35 μM | Function Assay | - | induces a conspicuous “inactivation” of the Kv2.1 current | 25962132 |
HEK‐CFTR | 2–50 μM | Function Assay | 0-12 min | induces a dose‐dependent iodide efflux | 25263207 |
HT-29 | 40 μM | Function Assay | 48 h | activates PP2A | 24997451 |
HT-29 | 40 μM | Growth Inhibition Assay | 0-72 h | inhibits cell growth time dependently | 24997451 |
HT-29 | 40 μM | Function Assay | 7 d | reduces colonosphere formation capability | 24997451 |
HT-29 | 40 μM | Apoptosis Assay | 48 h | induces an activation of caspase 3/7 | 24997451 |
HT-29 | 40 μM | Apoptosis Assay | 48 h | induces changes in the phosphorylation status of PP2A targets | 24997451 |
Huh-7 | 0-20 μM | Function Assay | 2 h | results in a dose-dependent increase in c-Myc expression at the protein and mRNA levels | 25109834 |
INA-6 | 0-100 μM | Cell Viability Assay | 72 h | induces cell death dose dependently | 26306624 |
L6 | 40 µM | Function Assay | 24 h | inhibits DMH1-induced Akt activation | 25247550 |
LNCaP | 10 μM | Function Assay | 12 h | induces a dramatic increase of CREB1 activity | 25548099 |
MDCK | 10 µM | Function Assay | 24 h | upregulates the expression of TGF-β1 and CTGF | 26202352 |
MDCK | 10 µM | Function Assay | 24 h | inhibits the increased expression of FN caused by TGF-β1 | 26202352 |
MIN6 | 10 μM | Function Assay | 3 h | increases D3 mRNA expression | 25241124 |
Mo-DCs | 50 μM | Function Assay | 24 h | promotes IL-23 production in the supernatant of zymosan stimulated Mo-DCs | 26412948 |
OCI-Ly1 | 40 μM | Function Assay | 1 h | induces the increment of cAMP concentrations | 25576220 |
OCI-Ly18 | 40 μM | Function Assay | 1 h | induces the increment of cAMP concentrations | 25576220 |
oocytes | 5 μM | Function Assay | 24 h | attenuates rh-insulin action on oocyte GVBD significantly | 25707854 |
OPM-2 | 0-100 μM | Cell Viability Assay | 72 h | induces cell death dose dependently | 26306624 |
PBMC | 50 μM | Function Assay | 24 h | inhibits the increased secretion of TNF induced by the DPE | 25866079 |
PC12 | 25 μM | Function Assay | 48 h | activates cAMP | 25769305 |
PC-3 | 40 µM | Function Assay | 2 h | leads to PP2A activation | 26023836 |
PC-3 | 40 µM | Cell Viability Assay | 24/48/72 h | decreases cell viability time dependently | 26023836 |
PCCL3 | 10 µM | Function Assay | 24 h | enhances DuOx2 promoter transcription activity | 25960956 |
Primary bovine chondrocytes | 5μM | Growth Inhibition Assay | 48 h | reverses the inhibitory effect of celecoxib on proliferation in growth plate chondrocytes | 25406016 |
RBMECs | 5 μM | Function Assay | 1 h | blocks the Rac1 inactivation induced by EMAP-II | 26358039 |
RBMECs | 5 μM | Function Assay | 1 h | inhibits EMAP-II-induced inactivation of Rap1 | 26044663 |
RBMECs | 0.05/0.5/5 μM | Function Assay | 0.25 h | increases cAMP concentration | 25416651 |
RBMECs | 5 μM | Function Assay | 1 h | blocks the activation of RhoA/ROCK induced by EMAP-II | 25416651 |
RBMECs | 5 μM | Function Assay | 1 h | prevents the EMAP-II-induced TEER value decrease | 25416651 |
RBMECs | 5 μM | Function Assay | 1 h | prevents the increase in HRP flux across the BTB induced by EMAP-II | 25416651 |
RBMECs | 5 μM | Function Assay | 1 h | inhibits the decreased of amount of ZO-1 in MFs induced by EMAP-II | 25416651 |
RBMECs | 5 μM | Function Assay | 1 h | reverses the changes in ZO-1 distribution seen with EMAP-II treatment | 25416651 |
RBMECs | 5 μM | Function Assay | 1 h | blocks the EMAP-II-induced change in MLC phosphorylation | 25416651 |
RBMECs | 5 μM | Function Assay | 1 h | blocks the actin cytoskeleton rearrangement seen with EMAP-II treatment | 25416651 |
RPMI 8226 | 0-100 μM | Cell Viability Assay | 72 h | induces cell death dose dependently | 26306624 |
SC | 0.5 μM | Function Assay | 24 h | mimicks the effect of cAMP analogs on O1 and MBP expression | 25705874 |
SC | 0.5 μM | Function Assay | 72 h | increases both Krox-20 and O1 expression in axon-related SCs but only Krox-20 | 25705874 |
SCG | 20 μM | Function Assay | - | reversibly suppresses IKV with a IC50 of 24.4 μM | 25962132 |
SCG | 100 μM | Function Assay | - | reduces the excitability of SCG neurons | 25962132 |
SH-SY5Y | 30 μM | Function Assay | 30 min | significantly increases the activation of PKA | 26025137 |
SH-SY5Y | 10 μM | Function Assay | 1 h | increases LUC activity | 25597433 |
SH-SY5Y | 10 μM | Function Assay | 1 h | increases AGC1 mRNA level | 25597433 |
SK-N-AS | 10 μM | Cell Viability Assay | 24/48 h | enhances time-dependently cellular viability | 25266063 |
SK-N-AS | 10 μM | Function Assay | 24 h | increases the cAMP levels | 25266063 |
SK-N-AS | 10 μM | Function Assay | 24 h | increases the expression of cyclin D1 | 25266063 |
SK-N-AS | 10 μM | Function Assay | 30 min | induces phosphorylation of β-catenin (ser675), p-GSK3β (ser9) and concomitant higher levels of active, unphosphorylated, β-catenin | 25266063 |
SK-N-AS | 10 μM | Function Assay | 10/30/60 min | increases levels of p-β-catenin (ser675) and induces accumulation of p-β-catenin (ser675) in (peri)nuclear regions | 25266063 |
SK-N-SH | 10 μM | Cell Viability Assay | 48 h | enhances SK-N-SH neuroblastoma cell viability | 25266063 |
Spinal cords | 1 μM | Function Assay | 30 min | stimulates cAMP levels | 26126926 |
SW480 | 40 μM | Function Assay | 48 h | activates PP2A | 24997451 |
SW480 | 40 μM | Growth Inhibition Assay | 0-72 h | inhibits cell growth time dependently | 24997451 |
SW480 | 40 μM | Function Assay | 7 d | reduces colonosphere formation capability | 24997451 |
SW480 | 40 μM | Apoptosis Assay | 48 h | induces an activation of caspase 3/7 | 24997451 |
SW480 | 40 μM | Apoptosis Assay | 48 h | induces changes in the phosphorylation status of PP2A targets | 24997451 |
ThGCs | 10 μM | Function Assay | 4 h | augments HIF1A levels that were stimulated by CoCl2 | 25433027 |
ThGCs | 10 μM | Function Assay | 4 h | increases CoCl2-induced EDN2 gene expression | 25433027 |
ThGCs | 10 μM | Function Assay | 3 h | inhibits the effect of H2O2 on EDN2 mRNA | 25433027 |
THP-1 | 1/10 μM | Function Assay | 2 h | suppresses MCP-1 production | 25154882 |
U266 | 0-100 μM | Cell Viability Assay | 72 h | induces cell death dose dependently | 26306624 |
UACC-647 | - | Function Assay | - | leads to a rise in cAMP levels (EC50 = 20.39 μM) | 25703025 |
UACC-647 | 10 μM | Function Assay | 15 min | inhibits ERK phosphorylation | 25703025 |
UACC-647 | 10 μM | Function Assay | 15 min | increases eEF2 phosphorylation levels | 25703025 |
ventricular cardiomyocytes | 0.01-10 μM | Function Assay | - | increases cAMP accumulation | 25203113 |
ventricular cardiomyocytes | 0.01-10 μM | Function Assay | - | evokes an inotropic response 120±15% above basal with an EC50 of 2.2 µM | 25203113 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT03390985 | - | - | Completed | - | - |
NCT02586883 | Idiopathic Dilation of the Bro... more >>nchi Collapse << | Not Applicable | Recruiting | April 2020 | France ... more >> Necker-Enfants Malades Hospital Recruiting Paris, France, 75015 Contact: Isabelle SERMET-GAUDELUS, MD, PhD +33144494887 isabelle.sermet@nck.aphp.fr Collapse << |
NCT03455153 | - | - | Completed | - | United Kingdom ... more >> Lindum Medical Practice Lincoln, Lincolnshire, United Kingdom, LN2 2JP Nettleham Medical Practice Lincoln, Lincolnshire, United Kingdom, LN2 2RS Birchwood Medical Practice Lincoln, Lincolnshire, United Kingdom, LN6 0QQ Collapse << |
NCT01920841 | Weight Loss | Not Applicable | Withdrawn(Study Design changed... more >> and will be resubmitted as a new study) Collapse << | - | United States, Louisiana ... more >> Pennington Biomedical Research Center Baton Rouge, Louisiana, United States, 70808 Collapse << |
NCT03652090 | - | - | Completed | - | - |
NCT02143349 | Metabolic Syndrome ... more >> Obesity Collapse << | Phase 3 | Unknown | May 2015 | Australia, Victoria ... more >> College of Health and Biomedicine Victoria University Recruiting St. Albans, Victoria, Australia, 14428 Contact: Dr. Xiao Su +61399192318 xiao.su@vu.edu.au Contact: A/Prof Michael Mathai +61399192211 michael.mathai@vu.edu.au Principal Investigator: Dr. Xiao Su Sub-Investigator: A/Prof Michael Mathai Collapse << |
NCT00864578 | - | - | Withdrawn(loss of interest bef... more >>ore enrolment started) Collapse << | June 2009 | Italy ... more >> Ophthalmology Department of the University Clinic Bari, Italy, I-70124 Collapse << |
NCT02807415 | - | - | Recruiting | June 2019 | Germany ... more >> Justus-Liebig-University Recruiting Gießen, Germany, 35385 Contact: Lutz Nährlich, MD 004964198557620 lutz.naehrlich@paediat.med.uni-giessen.de Contact: Claudia Rückes-Nilges, Dipl-Biol 004964198556945 claudia.rueckes-nilges@paediat.med.uni-giessen.de Principal Investigator: Lutz Nährlich, MD Sub-Investigator: Stefan Kuhnert, MD Hannover Medical School Recruiting Hannover, Germany, 30625 Contact: Burkhard Tümmler, MD PhD 00495115322920 tuemmler.burkhard@mh-hannover.de Contact: Christian Dopfer, MD 00495115326111 dopfer.christian@mh-hannover.de Principal Investigator: Burkhard Tümmler, MD PhD Sub-Investigator: Christian Dopfer, MD University of Heidelberg Recruiting Heidelberg, Germany, 69120 Contact: Marcus Mall, MD 00496221564502 Marcus.Mall@med.uni-heidelberg.de Contact: Simon Gräber, MD 004962215638926 Simon.Graeber@med.uni-heidelberg.de Principal Investigator: Marcus Mall, MD Sub-Investigator: Simon Gräber, MD Sub-Investigator: Susanne Dittrich, MD Collapse << |
NCT00863811 | - | - | Withdrawn(loss of interest bef... more >>ore enrolment started) Collapse << | July 2009 | Italy ... more >> Ophthalmology Department of the University Bari, Italy, I-70124 Collapse << |
NCT01254006 | Glaucoma | Not Applicable | Completed | - | Italy ... more >> Univerisity La Sapienza Latina, Italy Collapse << |
靶点 | Description | IC50 |
---|
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网